What are the detailed efficacy outcomes, dosing schedule, and safety considerations for the preferred first‑line systemic therapy (atezolizumab plus bevacizumab) in an adult with advanced hepatocellular carcinoma, Child‑Pugh A liver function, and ECOG 0‑1 performance status?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

阿替利珠单抗联合贝伐珠单抗治疗晚期肝细胞癌的详细疗效和安全性

对于Child-Pugh A级、ECOG 0-1的晚期肝细胞癌成人患者,阿替利珠单抗联合贝伐珠单抗是首选一线系统治疗方案,中位总生存期达19.2个月,显著优于索拉非尼的13.4个月。 1, 2

给药方案

标准剂量和频率

  • 阿替利珠单抗:可选择以下任一方案 3:

    • 840 mg 每2周一次,静脉输注
    • 1200 mg 每3周一次,静脉输注
    • 1680 mg 每4周一次,静脉输注

  • 贝伐珠单抗:15 mg/kg 每3周一次,静脉输注 3, 4

输注细节

  • 首次输注时间为60分钟
  • 如首次输注耐受良好,后续输注可缩短至30分钟
  • 同日给药时,先输注阿替利珠单抗,再输注贝伐珠单抗 3

疗效结果详述

生存获益(更新数据,中位随访15.6个月)

5提供了最成熟的疗效数据:

  • 总生存期(OS):

    • 阿替利珠单抗+贝伐珠单抗组:19.2个月(95% CI: 17.0-23.7)
    • 索拉非尼组:13.4个月(95% CI: 11.4-16.9)
    • 风险比(HR):0.66(95% CI: 0.52-0.85,p < 0.001)

  • 无进展生存期(PFS):

    • 阿替利珠单抗+贝伐珠单抗组:6.9个月(95% CI: 5.7-8.6)
    • 索拉非尼组:4.3个月(95% CI: 4.0-5.6)
    • 风险比:0.65(95% CI: 0.53-0.81,p < 0.001)

  • 客观缓解率(ORR):

    • 联合治疗组显著更高,约40-45% 2
    • 索拉非尼组约34%

长期生存数据

6的真实世界研究显示:

  • 36个月生存率:31.6%
  • 48个月生存率:19.6%
  • 60个月生存率:19.6%
  • 约30%的患者可存活超过3年

预后因素

独立预测长期生存的因素 6:

  • 无肝内肿瘤(OR = 5.36)
  • ALBI 1级肝功能(OR = 10.02)
  • 年龄≤70岁
  • 无大血管侵犯

安全性考虑

常见不良反应发生率

5报告的3/4级治疗相关不良事件:

  • 联合治疗组:43%
  • 索拉非尼组:46%

特定不良反应对比

  • 高血压:15%(联合组) vs 12%(索拉非尼)
  • 手足皮肤反应:0%(联合组) vs 8%(索拉非尼)
  • 腹泻:2%(联合组) vs 5%(索拉非尼)
  • AST升高:7%(联合组) vs 5%(索拉非尼)
  • 蛋白尿:>20%的患者出现 2

严重不良事件

  • 5级(致死性)治疗相关事件:2%(联合组) vs <1%(索拉非尼) 5

关键安全警告 3

必须监测的免疫相关不良反应:

  • 免疫介导的肺炎
  • 免疫介导的结肠炎
  • 免疫介导的肝炎
  • 免疫介导的内分泌病变
  • 免疫介导的肾炎

贝伐珠单抗特异性风险:

  • 胃肠道穿孔和瘘管形成
  • 出血风险增加
  • 血栓栓塞事件
  • 伤口愈合并发症

肝功能监测

基线评估要求

治疗前必须评估 1, 3:

  • 肝酶(AST/ALT)
  • 肌酐
  • 甲状腺功能
  • Child-Pugh评分
  • ALBI分级

治疗期间监测

7的研究显示:

  • 第2、3、4周期时ALBI评分有显著恶化(p = 0.001-0.015)
  • 后续治疗周期肝功能趋于稳定
  • 重要发现:轻度肝功能恶化(仅ALBI分级改变,无临床腹水、脑病、黄疸或消化道出血)不影响总生存期

特殊人群考虑

Child-Pugh B级患者

虽然指南推荐仅用于Child-Pugh A级患者 1, 2,但真实世界数据提供了重要信息:

Child-Pugh B7-8患者的疗效 8, 9:

  • 严重不良事件发生率:23.3%(可接受范围)
  • 客观缓解率:40-46.7%
  • 中位PFS:240天(约8个月)
  • 中位OS:470天(约15.6个月)
  • Child-Pugh评分在治疗期间基本维持稳定

关键预测因素:

  • mALBI分级≤2b的患者预后显著优于3级 9
  • Child-Pugh B7患者中位OS为9.1个月,B8-C12仅4.7个月 10

病因学影响

1明确指出:治疗选择不应受病因学影响(强推荐,100%共识)

然而,11的真实世界数据显示:

  • 乙型/丙型肝炎相关HCC的客观缓解率高于非病毒性HCC
  • 但这不应改变治疗决策

ALBI分级的预后价值

10证实ALBI分级在Child-Pugh A患者中具有独立预测价值:

  • ALBI 1级:中位OS 34.9个月
  • ALBI 2级:中位OS 14.2个月

治疗持续时间和停药决策

持续治疗的考虑

1指出:

  • 对于持续缓解的患者,停用免疫检查点抑制剂的后果目前尚不清楚
  • 停药决定应与患者讨论,基于现有的风险收益知识(弱推荐,100%共识)

疾病进展后的处理

  • 如患者仍有临床获益,可考虑在疾病进展后继续系统治疗 1
  • 对于孤立部位进展,可在继续系统治疗的同时进行局部治疗(弱推荐,95%共识)

禁忌症和注意事项

绝对禁忌症

3标注:无绝对禁忌症

相对禁忌症和特殊警告

贝伐珠单抗相关 4:

  • 活动性出血或近期出血史
  • 未控制的高血压
  • 计划手术(需停药至少28天)
  • 血栓栓塞事件高风险

免疫治疗相关 3:

  • 器官移植受者(排斥风险)
  • 自身免疫性疾病活动期

常见陷阱

  1. 不要在Child-Pugh B9或更高分数的患者中常规使用,除非在临床试验中 1
  2. 注意出血风险:贝伐珠单抗增加出血和血栓形成风险,这是选择治疗时的重要考虑因素 2
  3. 不要忽视基线肝功能评估:ALBI分级是重要的预后指标,应在治疗前评估 10, 6

真实世界疗效验证

12的美国社区肿瘤网络研究(374例患者)显示:

  • 总体人群中位OS:13.2个月
  • 符合试验标准的患者中位OS:16.5个月
  • 真实世界PFS:6.4个月(总体),9.4个月(符合试验标准者)

这些数据确认了该方案在常规临床实践中的有效性,即使在包括31% Child-Pugh B-C级和18% ECOG≥2的更广泛患者群体中。

References

9
Research

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Liver international : official journal of the International Association for the Study of the Liver, 2026

Related Questions

What is the recommended dose and administration schedule of atezolizumab and bevacizumab for hepatocellular carcinoma?
What is the recommended first-line treatment for a patient with advanced hepatocellular carcinoma (HCC), atezolizumab + bevacizumab or the STRIDE protocol?
Is it safe to proceed with Avastin (bevacizumab) and Tecentriq (atezolizumab) today in a patient with elevated bilirubin (bili) and alkaline phosphatase (alk phos) levels, and mild hypocalcemia?
Can clobetasol be prescribed for a rash suspected to be a drug‑induced reaction to tuberculosis therapy?
In a pleural effusion with protein 2.6 g/dL meeting Light’s criteria and 99% lymphocytic cells, what is the likely etiology and what are the recommended next diagnostic and therapeutic steps?
In patients with intracranial aneurysms, what factors determine the choice between endovascular therapy and microsurgical clipping?
What is Nuvaxovid (NVX‑CoV2373) COVID‑19 vaccine?
In a hospitalized patient with kidney, liver, and lung infections and a white blood cell count of 334 × 10⁹/L, what is the likely significance and recommended management?
What is the appropriate hydroxyurea dosing regimen for essential thrombocythemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.